LEIDEN, The Netherlands,
July 18, 2023 /PRNewswire/ --
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT
Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of
Directors has nominated Dr. Richard
Peters to become Pharming's new Chairman.
Pharming nominates Dr. Peters for the appointment as
Non-Executive Director for a term of four years at an upcoming
Extraordinary General Meeting of Shareholders (EGM). Information
regarding the EGM, including the notice to convene, will be shared
in a separate press release.
Until the appointment as Non-Executive Director by the EGM, Dr.
Peters will join the Board of Directors as an Observer.
Paul Sekhri, Chairman of the
Board, commented:
"After an extensive search, the Board is pleased to nominate
Dr. Richard Peters as the new
Chairman of the Board of Directors. Dr. Peters is a highly
respected and proven industry leader, who brings extensive medical
and commercial acumen for difficult-to-treat and rare diseases,
from development stage to large global biopharmaceutical companies.
I am delighted that Dr. Peters will become my successor following
his appointment by the general meeting."
Richard Peters
commented:
"I am honored to have been nominated to become the new
Chairman of the Board of Directors of Pharming, as successor to Mr.
Paul Sekhri. I look forward to
working together with the members of the Board of Directors and the
Executive Committee in helping propel Pharming to achieve its
long-term strategic objectives, guided by Pharming's clear vision
and mission to become the rare disease company of choice to serve
the unserved rare disease patient."
Dr. Richard Peters (60 years of
age, Belgian national, US citizen) has over 30 years of experience
in the healthcare industry and academia. He currently serves as
Non-Executive Director for Kineta (NASDAQ:KA) and Aprea
Therapeutics (NASDAQ:APRE), and is the founder and Executive
Chairman of TellBio (private company). He is also a corporate
advisor to Aura Biosciences.
Prior to these roles, Dr. Peters served as the Global Head for
the Rare Diseases business at Sanofi Genzyme, and CEO of two
Nasdaq-listed biotechnology companies: Yumanity Therapeutics and
Merrimack Pharmaceuticals. Earlier in his career, Dr. Peters held
medical leadership positions at Amgen, Onyx Pharmaceuticals,
Genzyme, and Sanofi, and is a founder of X4 Therapeutics
(NASDAQ:XFOR) and PIC Therapeutics (private). He has also served on
the faculty at the Massachusetts General Hospital, served as editor
for the journals SCIENCE and JAMA, and has published
over 100 editorial and research articles.
He completed Internal Medicine training at the Massachusetts
General Hospital and a Howard Hughes
post-doctoral fellowship at Harvard Medical
School; both in Boston, MA.
Dr. Peters holds an M.D. Degree and a PhD. in Pharmacology from the
Medical University of South Carolina,
Charleston, South Carolina, and
began his medical studies at the Universite Catholique de Louvain
in Belgium prior to immigrating to
the US.
About Pharming Group N.V.
Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is
a global biopharmaceutical company dedicated to transforming the
lives of patients with rare, debilitating, and life-threatening
diseases. Pharming is commercializing and developing an innovative
portfolio of protein replacement therapies and precision medicines,
including small molecules, biologics, and gene therapies that are
in early to late-stage development. Pharming is headquartered in
Leiden, Netherlands, and has
employees around the globe who serve patients in over 30 markets in
North America, Europe, the Middle
East, Africa, and
Asia-Pacific.
For more information, visit www.pharming.com and find us on
LinkedIn.
Forward-looking Statements
This press release may contain forward-looking statements.
Forward-looking statements are statements of future expectations
that are based on management's current expectations and assumptions
and involve known and unknown risks and uncertainties that could
cause actual results, performance, or events to differ materially
from those expressed or implied in these statements. These
forward-looking statements are identified by their use of terms and
phrases such as "aim", "ambition", ''anticipate'', ''believe'',
''could'', ''estimate'', ''expect'', ''goals'', ''intend'',
''may'', "milestones", ''objectives'', ''outlook'', ''plan'',
''probably'', ''project'', ''risks'', "schedule", ''seek'',
''should'', ''target'', ''will'' and similar terms and phrases.
Examples of forward-looking statements may include statements with
respect to timing and progress of Pharming's preclinical studies
and clinical trials of its product candidates, Pharming's clinical
and commercial prospects, and Pharming's expectations regarding its
projected working capital requirements and cash resources, which
statements are subject to a number of risks, uncertainties and
assumptions, including, but not limited to the scope, progress and
expansion of Pharming's clinical trials and ramifications for the
cost thereof; and clinical, scientific, regulatory and technical
developments. In light of these risks and uncertainties, and other
risks and uncertainties that are described in Pharming's 2022
Annual Report and the Annual Report on Form 20-F for the year ended
December 31, 2022, filed with the
U.S. Securities and Exchange Commission, the events and
circumstances discussed in such forward-looking statements may not
occur, and Pharming's actual results could differ materially and
adversely from those anticipated or implied thereby. All
forward-looking statements contained in this press release are
expressly qualified in their entirety by the cautionary statements
contained or referred to in this section. Readers should not place
undue reliance on forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and are
based on information available to Pharming as of the date of this
release. Pharming does not undertake any obligation to publicly
update or revise any.
Inside Information
This press release relates to the disclosure of information
that qualifies, or may have qualified, as inside information within
the meaning of Article 7(1) of the EU Market Abuse
Regulation.
For further public information, contact:
Pharming Group, Leiden, The
Netherlands
Michael Levitan, VP Investor Relations & Corporate
Communications
T: +1 (908) 705 1696
Heather Robertson, Investor
Relations & Corporate Communications Manager
E: investor@pharming.com
FTI Consulting, London,
UK
Victoria Foster
Mitchell/Alex Shaw/Amy
Byrne
T: +44 203 727 1000
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon
Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl
Photo -
https://mma.prnewswire.com/media/2155806/Pharming_Group_NV_Richard_Peters.jpg
Logo -
https://mma.prnewswire.com/media/2074393/Pharming_Group_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/pharming-to-nominate-industry-leader-dr-richard-peters-as-new-chairman-of-the-board-301879226.html
